High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer

Journal of Thoracic Oncology

Volumn 12, Issue 1, 2017, Pages 54-64

  Wiesweg, Marcel ^a   Eberhardt, Wilfried E E ^a   Reis, Henning ^a   Ting, Saskia ^a   Savvidou, Nikoleta ^a   Skiba, Charlotte ^a   Herold, Thomas ^a   Christoph, Daniel C ^a   Meiler, Johannes ^a   Worm, Karl ^a   Kasper, Stefan ^a   Theegarten, Dirk ^a   Hense, Jörg ^a   Hager, Thomas ^a   Darwiche, Kaid ^a   Oezkan, Filiz ^a   Aigner, Clemens ^a   Welter, Stefan ^a   Kühl, Hilmar ^a   Stuschke, Martin ^a   Schmid, Kurt W ^a   Schuler, Martin ^a   more..

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Concomitant mutations; EGFR; Lung adenocarcinoma; Pemetrexed; ROS1

Indexed keywords

AFATINIB; ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; CARBOPLATIN; CISPLATIN; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; K RAS PROTEIN; ONCOPROTEIN; OSIMERTINIB; PACLITAXEL; PEMETREXED; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PLATINUM DERIVATIVE; PROTEIN PIK3CA; PROTEIN ROS1; TUMOR MARKER; UNCLASSIFIED DRUG; PROTEIN TYROSINE KINASE; ROS1 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; CANCER CENTER; CANCER GROWTH; CANCER PATIENT; CLINICAL OUTCOME; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG TARGETING; DRUG WITHDRAWAL; EPIDEMIOLOGICAL DATA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GERMANY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METASTATIC LUNG CANCER; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NEPHROTOXICITY; OVERALL SURVIVAL; PREVALENCE; PROSPECTIVE STUDY; VERY ELDERLY; ADENOCARCINOMA; CANCER STAGING; FOLLOW UP; GENE REARRANGEMENT; GENETICS; LUNG TUMOR; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MUTATION; ONCOGENE; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; ONCOGENES; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; SURVIVAL RATE;

EID: 85011306206     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.08.137     Document Type: Conference Paper

References (48)

1. 1 Ferlay, J., Soerjomataram, I., Dikshit, R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.
2. 2 Alberti, W., Anderson, G., Bartolucci, A., Bell, D., Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ, 311, 1995, 899.
3. 3 NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non–small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26 (2008), 4617–4625.
4. 4 Johnson, D.H., Schiller, J.H., Bunn, P.A., Recent clinical advances in lung cancer management. J Clin Oncol 32 (2014), 973–982.
5. 5 Lee, C.K., Wu, Y.-L., Ding, P.N., et al. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis. J Clin Oncol 33 (2015), 1958–1965.
6. 6 Yang, J.C.-H., Wu, Y.-L., Schuler, M., et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16 (2015), 141–151.
7. 7 The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511 (2014), 543–550.
8. 8 Kris, M.G., Johnson, B.E., Berry, L.D., et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311 (2014), 1998–2006.
9. 9 Shaw, A.T., Kim, D.-W., Nakagawa, K., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368 (2013), 2385–2394.
10. 10 Solomon, B.J., Mok, T., Kim, D.-W., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371 (2014), 2167–2177.
11. 11 Shaw, A.T., Kim, D.-W., Mehra, R., et al. Ceritinib in ALK-rearranged non–small-cell lung cancer. N Engl J Med 370 (2014), 1189–1197.
12. 12 Ou, S.-H.I., Ahn, J.S., De Petris, L., et al. Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: an open-label, single-arm, global phase 2 study (NP28673). [abstract] J Clin Oncol, 33, 2015, 8008.
13. 13 Shaw, A.T., Ou, S.-H.I., Bang, Y.-J., et al. Crizotinib in ROS1-rearranged non–small-cell lung cancer. N Engl J Med 371 (2014), 1963–1971.
14. 14 Mazières, J., Zalcman, G., Crinò, L., et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol 33 (2015), 992–999.
15. 15 Wiesweg, M., Ting, S., Reis, H., et al. Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a comprehensive cancer center. Eur J Cancer 49 (2013), 3076–3082.
16. 16 Travis, W.D., Brambilla, E., Muller-Hermelink, H.K., Harris, C.C., (eds.) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart, 2004, IARC, Lyon, France, 9–122.
17. 17 Davies, K.D., Le, A.T., Theodoro, M.F., et al. Identifying and targeting ROS1 gene fusions in non–small cell lung cancer. Clin Cancer Res 18 (2012), 4570–4579.
18. 18 Hyman, D.M., Puzanov, I., Subbiah, V., et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373 (2015), 726–736.
19. 19 Planchard, D., Groen, H.J.M., Kim, T.M., et al. Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC). [abstract] J Clin Oncol, 33, 2015, 8006.
20. 20 Mazières, J., Peters, S., Lepage, B., et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 31 (2013), 1997–2003.
21. 21 Frampton, G.M., Ali, S.M., Rosenzweig, M., et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 5 (2015), 850–859.
22. 22 König, K., Peifer, M., Fassunke, J., et al. Implementation of amplicon parallel sequencing leads to improvement of diagnosis and therapy of lung cancer patients. J Thorac Oncol 10 (2015), 1049–1057.
23. 23 Ren, R., Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5 (2005), 172–183.
24. 24 Tzifi, F., Economopoulou, C., Gourgiotis, D., et al. The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias. Adv Hematol, 2012, 2012, 524308.
25. 25 Rikova, K., Guo, A., Zeng, Q., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131 (2007), 1190–1203.
26. 26 Bergethon, K., Shaw, A.T., Ou, S.-H.I., et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30 (2012), 863–870.
27. 27 Matsushime, H., Wang, L.H., Shibuya, M., Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule. Mol Cell Biol 6 (1986), 3000–3004.
28. 28 Acquaviva, J., Wong, R., Charest, A., The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta 1795 (2009), 37–52.
29. 29 Sonnenberg-Riethmacher, E., Walter, B., Riethmacher, D., Gödecke, S., Birchmeier, C., The c-ros tyrosine kinase receptor controls regionalization and differentiation of epithelial cells in the epididymis. Genes Dev 10 (1996), 1184–1193.
30. 30 Takeuchi, K., Soda, M., Togashi, Y., et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 18 (2012), 378–381.
31. 31 Vassal, G., Hoog Labouret, N., Le Deley, M.-C., et al. Biomarker-driven access to crizotinib in ALK-, MET-, or ROS1-positive malignancies in adults and children: feasibility of the French National Acse Program. [abstract] J Clin Oncol, 32, 2014, TPS2647.
32. 32 Rimkunas, V.M., Crosby, K.E., Li, D., et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non–small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 18 (2012), 4449–4457.
33. 33 Mescam-Mancini, L., Lantuéjoul, S., Moro-Sibilot, D., et al. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. Lung Cancer 83 (2014), 168–173.
34. 34 Cha, Y.J., Lee, J.S., Kim, H.R., et al. Screening of ROS1 Rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements. PLoS One, 9, 2014, e103333.
35. 35 Shan, L., Lian, F., Guo, L., et al. Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR. PLoS One, 10, 2015, e0120422.
36. 36 Viola, P., Maurya, M., Croud, J., et al. A validation study for the use of ROS1 immunohistochemical staining in screening for ROS1 translocations in lung cancer. J Thorac Oncol 11 (2016), 1029–1039.
37. 37 Riess, J.W., Padda, S.K., Bangs, C.D., et al. A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non–small-cell lung cancer patients harboring ROS1 gene rearrangements. Clin Lung Cancer 14 (2013), 592–595.
38. 38 Scheffler, M., Schultheis, A., Teixido, C., et al. ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Oncotarget 6 (2015), 10577–10585.
39. 39 Chen, Y.-F., Hsieh, M.-S., Wu, S.-G., et al. Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion–positive lung adenocarcinoma compared with in patients harboring other driver mutations in East Asian populations. J Thorac Oncol 11 (2016), 1140–1152.
40. 40 Drilon, A., Wang, L., Arcila, M.E., et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in “driver-negative” lung adenocarcinomas. Clin Cancer Res 21 (2015), 3631–3639.
41. 41 Heuckmann, J.M., Thomas, R.K., A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine. Ann Oncol 26 (2015), 1830–1837.
42. 42 Cai, W., Lin, D., Wu, C., et al. Intratumoral heterogeneity of ALK-rearranged and ALK/EGFR coaltered lung adenocarcinoma. J Clin Oncol 33 (2015), 3701–3709.
43. 43 Gainor, J.F., Varghese, A.M., Ou, S.-H.I., et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non–small cell lung cancer. Clin Cancer Res 19 (2013), 4273–4281.
44. 44 Yang, J.-J., Zhang, X.-C., Su, J., et al. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res 20 (2014), 1383–1392.
45. 45 Won, J.K., Keam, B., Koh, J., et al. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor. Ann Oncol 26 (2015), 348–354.
46. 46 Rossi, G., Baldi, L., Barbieri, F., Bertolini, F., Tiseo, M., Concomitant EGFR and KRAS mutations in ALK-rearranged lung cancer. Ann Oncol 26 (2015), 1035–1036.
47. 47 Bruin EC de, McGranahan, N., Mitter, R., et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346 (2014), 251–256.
48. 48 Zhang, J., Fujimoto, J., Zhang, J., et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346 (2014), 256–259.